Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia

International Journal of Cancer

Volumn 123, Issue 1, 2008, Pages 146-152

  Van Hende, Muriel Den ^a   Van Poelgeest, Mariette I E ^a   Van Der Hulst, Jeanette M ^a   De Jong, Joan ^a   Drijfhout, Jan W ^a   Fleuren, Gert Jan ^a   Valentijn, A Rob P M ^a   Wafelman, Amon R ^a   Slappendel, Gijs M ^a   Melief, Cornells J M ^a   Offringa, Rienk ^a   Van Der Burg, Sjoerd H ^a   Kenter, Gemma G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cellular immunity; ELISPOT; HPV16 delayed type hypersensitivity; Skin test

Indexed keywords

GAMMA INTERFERON; PROTEIN E2; PROTEIN E6; PROTEIN E7; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VIVO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LYMPHOCYTIC INFILTRATION; PAPULE; PATIENT SAFETY; PRIORITY JOURNAL; SKIN TEST; TH1 CELL; TH2 CELL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; ANTIGENS, VIRAL; CROSS-SECTIONAL STUDIES; CYTOKINES; DNA-BINDING PROTEINS; FEASIBILITY STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; HYSTERECTOMY; INJECTIONS, INTRADERMAL; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; SKIN; SKIN TESTS; UTERINE CERVICAL NEOPLASMS;

EID: 43949093431     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23502     Document Type: Article

References (39)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA, Landesman SH. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996;23:333-41.
4. Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E, Rylander E, Wadell G. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis 1995;22:119-27.
5. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
6. Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996;65:768-73.
7. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995;171:1026-30.
8. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
9. Kjaer SK, van den Brule AJ, Pauli G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572.
10. Remmink AJ, Walboomers JM, Heimerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
11. Ozsaran AA, Ates T, Dikmen Y, Zeytinoglu A, Terek C, Erhan Y, Ozacar T, Bilgic A. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999;20:127-30.
12. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC, Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-9.
13. Turk JL. Delayed hypersensitivity, 2nd edn. Amsterdam: Elsevier, 1975.
14. Black CA. Delayed type hypersensitivity: current theories with an historic perspective. Dermatol Online J 1999;5:7.
15. Poulter LW, Seymour GJ, Duke O, Janossy G, Panayi G. Immunohistological analysis of delayed-type hypersensitivity in man. Cell Immunol 1982;74:358-69.
16. Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN. Mantoux Test as a model for a secondary immune response in humans. Immunol Lett 2006;107:93-101.
17. Huebner RE, Schein MF, Bass JB, Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968-75.
18. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedom M, Knuth A. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162-9.
19. Rieser C, Ramoner R, Holtl L, Rogatsch H, Papesh C, Stenzl A, Bartsch G, Thurnher M. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 1999;63:151-9.
20. Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006; 119:2428-34.
21. Chambers MA, Stacey SN, Arrand JR, Stanley MA. Delayed-type hypersensitivity response to human papillomavirus type 16 E6 protein in a mouse model. J Gen Virol 1994;75 (Pt 1): 165-9.
22. Hopfl RM, Christensen ND, Angell MG, Kreider JW. Skin test to assess immunity against cottontail rabbit papillomavirus antigens in rabbits with progressing papillomas or after papilloma regression. J Invest Dermatol 1993;101:227-31.
23. Vambutas A, DeVoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR, van der Burg SH, Melief CJ. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a preclinical cottontail rabbit papillomavirus model. Vaccine 2005;23:5271-80.
24. Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, Widschwendter A, Haimbuchner S, Muller-Holzner E, Pawlita M, Pfister H, Fritsch P. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000;356:1985-6.
25. Hopfl R, Sandbichler M, Sepp N, Heim K, Muller-Holzner E, Wartusch B, Dapunt O, Jochmus-Kudielka I, ter Meulen J, Gissmann L. Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia. Lancet 1991;337:373-4.
26. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449-55.
27. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9.
28. van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter DJ, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 2006;118:675-83.
29. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636-41.
30. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren GJ, Kenter GG, Offringa R, van der Burg SH. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008; 122:486-94.
31. van der Burg SH, Kwappenberg KM, Geluk A, van der Kruk M, Pontesilli O, Hovenkamp E, Franken KL, van Meijgaarden KE, Drijfhout JW, Ottenhoff TH, Melief CJ, Offringa R. Identification of a conserved universal Th epitope in HIV-I reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. J Immunol 1999; 162:152-60.
32. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, et al. Natural T-helper immunity against human papillomavirus type 16 (HPV 16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001;91:612-8.
33. de Jong A, van der Hulst JM, Kenter GG, Drijfhout JW, Franken KL, Vermeij P, Offringa R, van der Burg SH, Melief CJ. Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer 2005;114:274-82.
34. Jeffries DJ, Hill PC, Fox A, Lugos M, Jackson-Sillah DJ, Adegbola RA, Brookes RH. Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia. Int J Tuberc Lung Dis 2006;10:192-8.
35. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67:354-61.
36. van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 2007;104:12087-92.
37. Wang S, Fan Y, Brunham RC, Yang X. IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection. Eur J Immunol 1999;29:3782-92.
38. Woodfolk JA, Platts-Mills TA. Diversity of the human allergen-specific T cell repertoire associated with distinct skin test reactions: delayed-type hypersensitivity-associated major epitopes induce Th1-and Th2-dominated responses. J Immunol 2001;167:5412-9.
39. Akcay A, Erdem Y, Altun B, Usalan C, Agca E, Yasavul U, Turgan C, Caglar S. The booster phenomenon in 2-step tuberculin skin testing of patients receiving long-term hemodialysis. Am J Infect Control 2003;31:371-4.